The FDA has published a plan to allow data from clinical trials to be reported to the agency as they occur in real time.

GSK is expecting several key late-stage readouts this year and, if they do not succeed, the company could change its team structure, CEO Luke Miels

MPM BioImpact, a leading biotech investor, is going all in on its strategy to take China-born drugs to the global stage. Over the past year,

AstraZeneca said it had stopped several mid- and late-stage trials of some of its pipeline programs in the past few months, potentially limiting some of

A study has found evidence that 11 cancers are becoming more common among young people in England, and points to a main driving factor.